Biocidal polymers and compounds comprising detectable moieties, coatings including same, and methods of making and using the same for controlling the growth of at least one bacteria, fungi, protozoa, or virus are disclosed.

Biocidal polymers and compounds comprising detectable moieties, coatings including same, and methods of making and using the same for controlling the growth of at least one bacteria, fungi, protozoa, or virus are disclosed.

Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model.

Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model.

The present application is directed to transdermal formulations comprising one or more capsaicinoinds, one or more 1,4-dialdehyde sesquiterpenes, a penetration enhancer comprising tetrahydropiperine and a transdermal formulation base. The formulations advantageously show improved color characteristics and cause less irritation compared to other known transdermal or topica formulations comprising capsaicinoinds.

A glutathione-cleavable prodrug is provided herein, as well as methods for its use in treating cancer, including triple negative breast cancer. The prodrug can be cleaved by glutathione under physiological conditions to generate a biologically active agent. The compound described herein is advantageous as the compound is fluorescent and can therefore be monitored within a subject.

A method for prophylactically or therapeutically treating an inflammatory disease and/or degenerative intervertebral disk disease in a subject is disclosed. The method includes administering to the subject an effective amount of a coumarin derivative represented by formula (I), or a pharmaceutically acceptable salt or hydrate thereof: ##STR00001##
Each of R1 and R2 is independently (a) phenyl optionally substituted with alkoxy, alkyl, cyano, nitro, hydroxy, trifluoromethyl, amino, carboxy, alkoxycarbonyl, phenyl, or one or two halogen(s), (b) pyridyl, (c) alkyl, or (d) thienyl.

Quantum dot ligand, preparation method and quantum dot light-emitting device are provided. The quantum dot ligand has a structural general formula as shown in Formula I, XYZ Formula I; wherein X is a coordination group for forming a coordination bond with a quantum dot body; Z is a dissolving group, and the dissolving group is selected from a polar group; Y includes a linking group and a photosensitive group connected with each other, and the linking group is connected between the coordination group and the photosensitive group; the linking group is selected from an alkylene group; the photosensitive group is capable of undergoing bond breaking under light condition such that the quantum dot ligand decomposes into a first unit including the coordination group and the linking group, and a second unit including the dissolving group, and polarity of the first unit is less than polarity of the second unit.

Quantum dot ligand, preparation method and quantum dot light-emitting device are provided. The quantum dot ligand has a structural general formula as shown in Formula I, XYZ Formula I; wherein X is a coordination group for forming a coordination bond with a quantum dot body; Z is a dissolving group, and the dissolving group is selected from a polar group; Y includes a linking group and a photosensitive group connected with each other, and the linking group is connected between the coordination group and the photosensitive group; the linking group is selected from an alkylene group; the photosensitive group is capable of undergoing bond breaking under light condition such that the quantum dot ligand decomposes into a first unit including the coordination group and the linking group, and a second unit including the dissolving group, and polarity of the first unit is less than polarity of the second unit.

A glutathione-cleavable prodrug is provided herein, as well as methods for its use in treating cancer, including triple negative breast cancer. The prodrug can be cleaved by glutathione under physiological conditions to generate a biologically active agent. The compound described herein is advantageous as the compound is fluorescent and can therefore be monitored within a subject.